Study on AAV-mediated gene therapy for diabetes in humanized liver mouse to predict efficacy in humans

Biochem Biophys Res Commun. 2016 Sep 23;478(3):1254-60. doi: 10.1016/j.bbrc.2016.08.104. Epub 2016 Aug 19.

Abstract

Most in vivo studies on the conversion to insulin-producing cells with AAV carrying PDX1 gene are performed in rodents. However, there is little information regarding Adeno-associated virus (AAV) carrying PDX1 gene transduced to human liver in vivo because accidental death caused by unpredicted factors cannot be denied, such as the hypoglycemic agent troglitazone with hepatic failure. Here we aim to confirm insulin secretion from human liver transduced with AAV carrying PDX1 gene in vivo and any secondary effect using a humanized liver mouse. As the results, AAV2-PG succeeded to improve the hyperglycemia of STZ-induced diabetic humanized liver mice. Then, the analysis of humanized liver mice revealed that the AAV2-PG was more transducible to humanized liver area than to mouse liver area. In conclusion, the humanized liver mouse model could be used to examine AAV transduction of human hepatocytes in vivo and better predict clinical transduction efficiency than nonhumanized mice.

Keywords: Adeno-associated virus; Diabetes; Humanized liver mouse; PDX1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Dependovirus / metabolism*
  • Diabetes Mellitus, Experimental / complications
  • Diabetes Mellitus, Experimental / genetics*
  • Diabetes Mellitus, Experimental / therapy*
  • Genetic Therapy*
  • Green Fluorescent Proteins / metabolism
  • Homeodomain Proteins / metabolism
  • Humans
  • Hyperglycemia / complications
  • Hyperglycemia / therapy
  • Insulin / metabolism
  • Mice
  • Mice, Transgenic
  • Trans-Activators / metabolism
  • Transduction, Genetic

Substances

  • Homeodomain Proteins
  • Insulin
  • Trans-Activators
  • pancreatic and duodenal homeobox 1 protein
  • Green Fluorescent Proteins